Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel.
Reshma L MahtaniAlexander NiyazovBhakti ArondekarKatie LewisAlex RiderLucy MasseyMichael Patrick LuxPublished in: BMC cancer (2022)
The PRO findings in this real-world population of patients with gBRCA1/2mut HER2- ABC complement those from the pivotal clinical trials, providing further support for treatment with PARPi in these patients.
Keyphrases
- patient reported outcomes
- epidermal growth factor receptor
- clinical trial
- endothelial cells
- end stage renal disease
- advanced non small cell lung cancer
- newly diagnosed
- primary care
- ejection fraction
- emergency department
- prognostic factors
- locally advanced
- anti inflammatory
- squamous cell carcinoma
- induced pluripotent stem cells
- study protocol
- breast cancer risk
- replacement therapy